Escitalopram

Generic Name: Escitalopram

Brand Names: Cipralex, Lexapro

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₁FN_₂O

CAS Number: 128196-01-0

Unique Ingredient Identifier: 4O4S742ANY

Background: Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic citalopram. It is used to restore serotonergic function in the treatment of depression and anxiety. Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with...

Indication: Escitalopram is indicated for the acute and maintenance treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years old and older and for the acute treatment of generalized anxiety disorder (GAD) in adults and pediatric patients 7 years old and older. It is additionally indicated for symptomatic relief of obsessive-compulsive disor...

Associated Conditions: Anxiety, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD)

Associated Therapies: -

Clinical Trials

Acamprosate Added to Escitalopram and Behavioral Treatment for Comorbid Depression and Alcoholism

Phase 4

Completed

Conditions: Major Depressive Disorder
Alcohol Abuse
Alcohol Dependence

Interventions: Drug: acamprosate
Drug: escitalopram
Behavioral: Medical management
Drug: Placebo

First Posted Date: 2007-03-27

Last Posted Date: 2012-07-09

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 23

Registration Number: NCT00452543

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Escitalopram and Sleep Architecture in Patients With Major Depressive Disorder

Phase 4

Conditions: Major Depressive Disorder

First Posted Date: 2007-03-02

Last Posted Date: 2007-03-02

Lead Sponsor: Sheba Medical Center

Target Recruit Count: 25

Registration Number: NCT00442481

Locations: 🇮🇱
Sheba Medical Center, Department of psychiatry, Tel Hashomer, Israel

Discontinuation of Antipsychotics and Antidepressants Among Patients With BPSD

Phase 4

Completed

Conditions: Dementia

Interventions: Drug: Risperidone
Drug: Olanzapine
Drug: Haloperidole
Drug: Quetiapin
Drug: Escitalopram
Drug: Citalopram
Drug: Sertralin

First Posted Date: 2007-02-09

Last Posted Date: 2007-08-24

Lead Sponsor: Sykehuset Innlandet HF

Target Recruit Count: 24

Registration Number: NCT00433121

Locations: 🇳🇴
Sykehuset Innlandet HF - Sanderud, Ottestad, Oppland, Norway

Efficacy and Safety of SR58611A co-Administered With Escitalopram in Adults With Major Depressive Disorder

Phase 3

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: SR58611A
Drug: placebo
Drug: escitalopram

First Posted Date: 2007-02-08

Last Posted Date: 2009-03-25

Lead Sponsor: Sanofi

Target Recruit Count: 510

Registration Number: NCT00432614

Locations: 🇹🇷
Sanofi-Aventis Administrative Office, Istanbul, Turkey

Galantamine Augmentation of Escitalopram for Treatment of Depression

Phase 4

Terminated

Conditions: Depression

First Posted Date: 2007-01-18

Last Posted Date: 2007-01-18

Lead Sponsor: Indiana University School of Medicine

Target Recruit Count: 20

Registration Number: NCT00423969

Locations: 🇺🇸
IU Adult Psychiatric Clinic, Indianapolis, Indiana, United States

A Study for Participants With Major Depression

Phase 2

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Placebo
Drug: LY2216684
Drug: Escitalopram

First Posted Date: 2007-01-09

Last Posted Date: 2018-04-27

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 469

Registration Number: NCT00420004

Locations: 🇷🇴
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lasi, Romania

Escitalopram in Depressive Patients With Acute Coronary Artery Syndrome

Phase 4

Completed

Conditions: Coronary Disease
Depressive Disorder

Interventions: Drug: Placebo
Drug: Escitalopram

First Posted Date: 2007-01-08

Last Posted Date: 2013-06-13

Lead Sponsor: Chonnam National University Hospital

Target Recruit Count: 300

Registration Number: NCT00419471

Locations: 🇰🇷
Chonnam National University Hospital, Gwangju, Korea, Republic of

An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder

Phase 3

Completed

Conditions: Generalized Anxiety

Interventions: Drug: Placebo
Drug: Escitalopram
Drug: Saredutant

First Posted Date: 2006-12-29

Last Posted Date: 2016-05-24

Lead Sponsor: Sanofi

Target Recruit Count: 365

Registration Number: NCT00417118

Locations: 🇹🇷
Sanofi-Aventis Administrative Office, Istanbul, Turkey

An Eight-week Study Evaluating the Efficacy of a 100mg Dose of Saredutant Once Daily, in Elderly Patients With Major Depressive Disorder

Phase 3

Completed

Conditions: Depressive Disorder

Interventions: Drug: saredutant (SR48968)
Drug: escitalopram
Drug: placebo

First Posted Date: 2006-12-22

Last Posted Date: 2016-05-24

Lead Sponsor: Sanofi

Target Recruit Count: 393

Registration Number: NCT00415142

Locations: 🇹🇷
Sanofi-Aventis Administrative Office, Istanbul, Turkey

Evaluation of the Effects of Duloxetine on Norepinephrine

Phase 1

Completed

Conditions: Major Depressive Disorder

First Posted Date: 2006-12-21

Last Posted Date: 2007-06-12

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 35

Registration Number: NCT00414323

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy